Uphold Mesh for the Surgical Treatment of Uterine-predominant Prolapse

Inclusion Criteria: * The patient must have given his/her informed and signed consent * The patient must be insured or beneficiary of a health insurance plan * The patient is available for 12 months of follow-up * Patients with symptoms and altered quality of life in relation to uterine or post-hysterectomy vault prolapse * Patients who are receiving the UpholdTM LITE mesh Kit * Female patients \>= years who have no desire of future pregnancy * Diagnosed with pelvic organ prolapse and \>= ICS POP-Q Stage 2 Symptomatic Prolapse apical compartment (uterine or vault), associated with ICS POP-Q Stage 2 or 3 Symptomatic Prolapse anterior compartment (point Ba \>= -1 * Patients willing to complete quality of life questionnaire at baseline (pre-procedure) and at 6 weeks, 6 and 12 months post-procedure Exclusion Criteria: * The patient is participating in another study * The patient is in an exclusion period determined by a previous study * The patient is under judicial protection, under tutorship or curatorship * The patient refuses to sign the consent * It is impossible to correctly inform the patient * The patient is pregnant, parturient, or breastfeeding * Patients who are not receiving the UpHoldTM LITE mesh Kit * Patients \< 50 years * Patients qho, according to the clinical judgment of the investigator, are not suitable for this study * Patients who are considering future pregnancies * Patients whose pelvic organ prolapse is a \<= 1 ICS Stage * Patients requiring Posterior Graft procedure * Patients with known or suspected hypersensitivity to polypropylene * Patients with any pathology which ould compromise implant placement * Patients with any pathology which ould compromise implant placement as mentioned in the device instruction manual * Patients with any pathology that would limit blood supply and compromise healing * Patients with blood coagulation disorder (associated current level coagulation) * Patients with autoimmune connective tissue disease * Patients with upper urinary tract obstruction and renal insufficiency * Patients with local or systemic infection